Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550238 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 459
- Enrollment target
NCT00550238: Completed Phase 3 study, sponsored by ACADIA Pharmaceuticals.
NCT00550238 is a Phase 3 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 459 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00550238, a Phase 3 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 459 participants
- Enrollment target
Study Summary
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
Primary Outcome
Number (%) of patients with drug-related treatment-emergent AEs (i.e. AEs reported by the Investigator as possibly, probably, or highly probably related to study drug)
Interventions
- DRUG Pimavanserin tartrate (ACP-103)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2007-07 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 3 |
What the finished NCT00550238 record still lists
NCT00550238 is an interventional study that assigns participants to a tested intervention. The registered 459 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin tartrate (ACP-103) is the first listed.
NCT00550238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00550238 about?
NCT00550238 is a clinical study titled "A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis". To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
What is the current status of trial NCT00550238?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 459 participants. The study started on 2007-07. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT00550238?
The interventions under investigation include: Pimavanserin tartrate (ACP-103) (DRUG).
Who is sponsoring clinical trial NCT00550238?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00550238's enrollment target sits among peer trials
459 827th of 2000 higher than 1,174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia